Share This Article:

Expression of Cyclooxygenase-2 and Transforming Growth Factor-Beta 1 in Patients with the Early Recurrence of Hepatocellular Carcinoma Following Hepatectomy

Abstract Full-Text HTML XML Download Download as PDF (Size:687KB) PP. 322-331
DOI: 10.4236/ss.2012.36064    3,041 Downloads   4,742 Views   Citations


Background: Cyclooxygenase-2 (COX-2) and transforming growth factor-beta1 (TGF-β1) are modulated in variety cancers including Hepatocellular carcinoma (HCC). However, there is a paucity of data concerning their role in the pathologic process of recurrence of HCC following hepatectomy. We herein assessed the role of the hepatic expression of COX-2 and TGF-β as predictors for patients with early recurrence within 2 years of HCC diagnosis. Methods: Sixty patients with HCC who underwent curative hepatectomy between 2000 and 2003 were entered in the present study. The immunoreactivity and distribution patterns of COX-2 and TGF-β1 were examined in both the HCC and the adjacent nonHCC tissues of the liver. Risk factors of tumor recurrence within 2 years, including COX-2 and TGF-β1 expression, were investigated by univariate and multivariate analyses. Results: Among 60 patients, 31 patients had early recurrences within 2 years and 14 patients recurred after 2 years following surgery. Patients with low COX-2 expression in the HCC tissues and adjacent nonHCC tissues had favorable disease-free survival (p = 0.002 and p < 0.001, respectively) and patients with positive TGF-β1 expression in the nonHCC tissues had also longer disease-free survival (p = 0.045). Based on the expression patterns of COX-2 and TGF-β1, patients with low COX-2 and positive TGF-β1 expression in the nonHCC tissues had favorable overall and disease-free survival (p < 0.001, respectively). Conclusions: Increased COX-2 expression and decreased TGF-β1 signaling in nontumor tissues suggested high risk of recurrence and poor survival to the HCC patients following hepatectomy.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

T. Nakase, M. Ueno, K. Uchiyama, N. Matsuura and H. Yamaue, "Expression of Cyclooxygenase-2 and Transforming Growth Factor-Beta 1 in Patients with the Early Recurrence of Hepatocellular Carcinoma Following Hepatectomy," Surgical Science, Vol. 3 No. 6, 2012, pp. 322-331. doi: 10.4236/ss.2012.36064.


[1] K. Uchiyama, K. Mori, K. Tabuse, M. Ueno, S. Ozawa, T. Nakase, M. Kawai, M. Tani, H. Tanimura and H. Yamaue, “Assessment of Liver Function for Successful Hepatectomy in Patients with Hepatocellular Carcinoma with Impaired Hepatic Function,” Journal of Hepato-Biliary-Pancreatic Surgery, Vol. 15, No. 6, 2008, pp. 596-602. doi:10.1007/s00534-007-1326-2
[2] M. Ueno, K. Uchiyama, S. Ozawa, S. Hayami, S. Kiriyama and H. Yamaue, “A New Prediction Model of Postoperative Complications after Major Hepatectomy for Hepatocellular Carcinoma,” Digestive Surgery, Vol. 26, No. 5, 2009, pp. 392-399. doi:10.1159/000229973
[3] S. A. Shah, S. P. Cleary, A. C. Wei, I. Yang, B. R. Taylor, A. W. Hemming, B. Langer, D. R. Grant, P. D. Greig and S. Gallinger, “Recurrence after Liver Resection for Hepatocellular Carcinoma: Risk Factors, Treatment, and Outcomes,” Surgery, Vol. 141, No. 3, 2007, pp. 330-339. doi:10.1016/j.surg.2006.06.028
[4] M. Ueno, K. Uchiyama, S. Ozawa, T. Nakase, N. Togo, S. Hayami and H. Yamaue, “Prognostic Impact of Treatment Modalities on Patients with Single Nodular Recurrence of Hepatocellular Carcinoma,” Surgery Today, Vol. 39, No. 8, 2009, pp. 675-681. doi:10.1007/s00595-008-3942-0
[5] S. Yoshioka, I. Takemasa, H. Nagano, N. Kittaka, T. Noda, H. Wada, S. Kobayashi, S. Marubashi, Y. Takeda, K. Umeshita, K. Dono, K. Matsubara and M. Monden, “Molecular Prediction of Early Recurrence after Resection of Hepatocellular Carcinoma,” European Journal of Cancer, Vol. 45, No. 5, 2009, pp. 881-889. doi:10.1016/j.ejca.2008.12.019
[6] M. E. Herceg, A. C. Tsiatis, J. L. Halpern, G. E. Holt, H. S. Schwartz, V. L. Keedy and J. M. Cates, “Cyclooxygenase 2 Expression in Soft Tissue Leiomyosarcoma,” Anticancer Research, Vol. 29, No. 8, 2009, pp. 2913-2917.
[7] C. J. Liu, T. C. Hsia, R. F. Wang, C. W. Tsai, C. C. Chu, L. W. Hang, C. H. Wang, H. Z. Lee, R. Y. Tsai and D. T. Bau, “Interaction of Cyclooxygenase 2 Genotype and Smoking Habit in Taiwanese Lung Cancer Patients,” Anticancer Research, Vol. 30, No. 4, 2010, pp. 1195-1199.
[8] J. G. Kim, Y. S. Chae, S. K. Sohn, J. H. Moon, H. M. Ryoo, S. H. Bae, Y. Kum, S. W. Jeon, K. H. Lim, B. M. Kang, I. J. Park, G. S. Choi and S. H. Jun, “Prostaglandin Synthase 2/Cyclooxygenase 2 (PTGS2/COX2) 8473T>C Polymorphism Associated with Prognosis for Patients with Colorectal Cancer Treated with Capecitabine and Oxaliplatin,” Cancer Chemotherapy and Pharmacology, Vol. 64, No. 5, 2009, pp. 953-960. doi:10.1007/s00280-009-0947-3
[9] A. T. Panagopoulos, C. L. Lancellotti, J. C. Veiga, P. H. de Aguiar and A. Colquhoun, “Expression of Cell Adhesion Proteins and Proteins Related to Angiogenesis and Fatty Acid Metabolism in Benign, Atypical, and Anaplastic Meningiomas,” Journal of Neuro-Oncology, Vol. 89, No. 1, 2008, pp. 73-87. doi:10.1007/s11060-008-9588-3
[10] M. G. Alexandrow and H. L. Moses, “Transforming Growth Factor Beta and Cell Cycle Regulation,” Cancer Research, Vol. 55, No. 7, 1995, pp. 1452-1457.
[11] H. You, W. Ding and C. B. Rountree, “Epigenetic Regulation of Cancer Stem Cell Marker CD133 by Transforming Growth Factor-Beta,” Hepatology, Vol. 51, No. 5, 2010, pp. 1635-1644. doi:10.1002/hep.23544
[12] Y. S. Guo, Z. Chen, X. D. Wen, T. C. Ko, C. M. Townsend Jr. and M. R. Hellmich, “Synergistic Regulation of COX-2 Expression by Bombesin and Transforming Growth Factor-Beta,” Digestive Diseases and Sciences, Vol. 53, No. 8, 2008, pp.2045-2052. doi:10.1007/s10620-007-0122-9
[13] D. Saha, P. K. Datta, H. Sheng, J. D. Morrow, M. Wada, H. L. Moses and R. D. Beauchamp, “Synergistic Induction of cyclooxygenase-2 by Transforming Growth Factor-Beta1 and Epidermal Growth Factor Inhibits Apoptosis in Epithelial Cells,” Neoplasia, Vol. 1, No. 6, 1999, pp. 508-517. doi:10.1038/sj.neo.7900051
[14] H. Koga, S. Sakisaka, M. Ohishi, T. Kawaguchi, E. Taniguchi, K. Sasatomi, M. Harada, T. Kusaba, M. Tanaka, R. Kimura, Y. Nakashima, O. Nakashima, M. Kojiro, T. Kurohiji and M. Sata, “Expression of Cyclooxygenase-2 in Human Hepatocellular Carcinoma: Relevance to Tumor Dedifferentiation,” Hepatology, Vol. 29, No. 3, 1999, pp. 688-696 doi:10.1002/hep.510290355
[15] A. S. Cheng, H. L. Chan, W. K. Leung, K. F. To, M. Y. Go, J. Y. Chan, C. T. Liew and J. J. Sung, “Expression of HBx and COX-2 in Chronic Hepatitis B, Cirrhosis and Hepatocellular Carcinoma: Implication of HBx in Upregulation of COX-2,” Modern Pathology, Vol. 17, 2004, pp. 1169-1179. doi:10.1038/modpathol.3800196
[16] N. Nishida, T. Nagasaka, T. Nishimura, I. Ikai, C. R. Boland and A. Goel, “Aberrant Methylation of Multiple Tumor Suppressor Genes in Aging Liver, Chronic Hepatitis, and Hepatocellular Carcinoma,” Hepatology, Vol. 47, No. 3, 2008, pp. 908-918. doi:10.1002/hep.22110
[17] A. J. Dannenberg and K. Subbaramaiah, “Targeting Cyclooxygenase-2 in Human Neoplasia: Rationale and Promise,” Cancer Cell, Vol. 4, No. 6, 2003, pp. 431-436. doi:10.1016/S1535-6108(03)00310-6
[18] M. Kondo, H. Yamamoto, H. Nagano, J. Okami, Y. Ito, J. Shimizu, H. Eguchi, A. Miyamoto, K. Dono, K. Umeshita, N. Matsuura, K. Wakasa, S. Nakamori, M. Sakon and M. Monden, “Increased Expression of COX-2 in Nontumor Liver Tissue Is Associated with Shorter Disease-Free Survival in Patients with Hepatocellular Carcinoma,” Clinical Cancer Research, Vol. 5, No. 12, 1999, pp. 4005-4012.
[19] Y. F. He, J. Jin, W. Wei, Y. Chang, B. Hu, C. S. Ji, W. D. Jia, X. Q. Wang, K. Chen and J. Chen, “Overexpression of Cyclooxygenase-2 in Noncancerous Liver Tissue Increases the Postoperative Recurrence of Hepatocellular Carcinoma in Patients with Hepatitis B Virus-Related Cirrhosis,” Canadian Journal of Gastroenterology, Vol. 24, No. 7, 2010, pp. 435-440.
[20] S. Morinaga, K. Tarao, Y. Yamamoto, Y. Nakamura, Y. Rino, K. Miyakawa, S. Ohkawa, M. Akaike, Y. Sugimasa and S. Takemiya, “Overexpressed Cyclo-oxygenase-2 in the Background Liver Is Associated with the Clinical Course of Hepatitis C Virus-Related Cirrhosis Patients after Curative Surgery for Hepatocellular Carcinoma,” Journal of Gastroenterology and Hepatology, Vol. 22, No. 8, 2007, pp. 1249-1255. doi:10.1111/j.1440-1746.2006.04367.x
[21] S. Ozawa, K. Uchiyama, M. Nakamori, K. Ueda, M. Iwahashi, H. Ueno, Y. Muragaki, A. Ooshima and H. Yamaue, “Combination Gene Therapy of HGF and Truncated Type II TGF-beta Receptor for Rat Liver Cirrhosis after Partial Hepatectomy,” Surgery, Vol. 139, No. 4, 2006, pp.563-573. doi:10.1016/j.surg.2005.10.003
[22] J. Shao, H. Sheng, R. Aramandla, M. A. Pereira, R. A. Lubet, E. Hawk, L. Grogan, I. R. Kirsch, M. K. Washington, R. D. Beauchamp and R. N. DuBois, “Coordinate Regulation of Cyclooxygenase-2 and TGF-beta1 in Replication Error-Positive Colon Cancer and Azoxymethane-Induced Rat Colonic Tumors,” Carcinogenesis, Vol. 20, No. 2, 1999, pp. 185-191. doi:10.1093/carcin/20.2.185
[23] C. Han, A. J. Demetris, Y. Liu, J. H. Shelhamer and T. Wu, “Transforming Growth Factor-Beta (TGF-beta) Activates Cytosolic Phospholipase A2alpha (cPLA2alpha)-Mediated Prostaglandin E2 (PGE)2/EP1 and Peroxisome Proliferator-Activated Receptor-Gamma (PPAR-gamma)/ Smad Signaling Pathways in Human Liver Cancer Cells. A Novel Mechanism for Subversion of TGF-beta-induced Mitoinhibition,” Journal of Biological Chemistry, Vol. 279, No. 43, 2004, pp. 44344-44354. doi:10.1074/jbc.M404852200

comments powered by Disqus

Copyright © 2018 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.